Specifications
- Pk:100 µG
- Protein/peptide type:Recombinant
- Source:HEK293 cells
- Species:Human
- Biological activity:Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein E3 is immobilized at 1μg/ml (100μl/well), the concentration of Recombinant Human VLDLR that produces 50% of the optimal binding response is found to be approximately 0. 03 - 0. 15μg/ml.
- Protein synonyms:RP11-320E16.1|VLDL receptor|VLDLRCH|FLJ35024|VLDLR|CHRMQ1
- Protein/peptide name:VLDLR
- Purity:>97% as determined by SDS-PAGE.
- Molecular weight:86 kDa
- Formulation:Lyophilized, PBS, pH7.4
- Tested applications:Western Blot
Specifications
About this item
The very-low-density-lipoprotein receptor (VLDL-R) is a lipoprotein receptor that shows considerable similarity to the lowdensity-lipoprotein receptor. VLDL R is a 130 kDa type I transmembrane protein in the LDL receptor family that plays a significant role in lipid metabolism and in nervous system development and function .This receptor has been suggested to be important for the metabolism of apoprotein-E-containing triacylglycerol-rich lipoproteins, such as very-low-densitylipoprotein (VLDL), beta-migrating VLDL and intermediate-density lipoprotein. It is also one of the receptors of reelin, an extracellular matrix protein which regulates the processes of neuronal migration and synaptic plasticity. In humans, the VLDL-R is encoded by the VLDLR gene.
A rare neurological disorder first described in the 1970s under the name "disequilibrium syndrome" is now considered to be caused by the disruption of VLDLR gene. The disorder was renamed VLDLR-associated cerebellar hypoplasia (VLDLRCH) after a 2005 study. It is associated with parental consanguinity and found in secluded communities such as the Hutterites. VLDLRCH is one of the two known genetic disorders caused by a disruption of reelin signaling pathway, along with Norman-Roberts syndrome.